B

Baroness Ritchie of Downpatrick (Lab)

Speaking in the House of Lords on 9 November 2026

Debate

Health Bill

Contribution

My Lords, I come to this debate as someone who is a breast cancer survivor of some eight years and who has been involved in a cancer trial—a double-blind aspirin trial. I do not know whether I was taking aspirin, but I will find out next year when the results of that trial will be revealed. I am somebody who, from practice, firmly believes in cancer outcomes. I believe there needs to be concentration on cancer outcomes, on survival and on an expeditious way to ensure that patients have ready access, especially for rare cancers. Genomics is telling us so much about the type and the content of cancer tumours that we need to work at pace to ensure that those treatments and new treatments are available to deal with them. I have every confidence that the Government will be able to facilitate that, but the challenging issues are around radiotherapy times, and the intensification of radiotherapy and those treatments. I remember, from my first diagnosis, being told that everybody’s tumour is different, even though you may have breast cancer, because that is the collective term. Therefore, the idea and the objective is to focus that treatment on the content of the tumour that you have, which is particular to you. Treatments are dedicated to the needs of patients; I would like to think that was continued as part of our Health Bill and of treating cancer patients generally.

More from Baroness Ritchie of Downpatrick (Lab)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.